576 related articles for article (PubMed ID: 15117890)
21. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri.
Friedman AJ; Daly M; Juneau-Norcross M; Rein MS; Fine C; Gleason R; Leboff M
J Clin Endocrinol Metab; 1993 Jun; 76(6):1439-45. PubMed ID: 8501148
[TBL] [Abstract][Full Text] [Related]
22. Morphologic patterns of human endometrial epithelium in women with uterine myomata treated with leuprorelin acetate.
Palmara V; Triolo O; Benedetto V; Lo Re C; Sturlese E; Retto G; Santoro G
Gynecol Obstet Invest; 2010; 69(2):131-5. PubMed ID: 19996602
[TBL] [Abstract][Full Text] [Related]
23. Effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
Cramer SF
Arch Pathol Lab Med; 1998 Dec; 122(12):1045-6. PubMed ID: 9870847
[No Abstract] [Full Text] [Related]
24. [Effect of GnRH analogues on bone density in the vertebral column and the femur].
Perrone G; Galoppi P; Critelli C; Bazzoffi R; Capri O; Barillaro F; Zichella L
Minerva Ginecol; 1995 Oct; 47(10):461-5. PubMed ID: 8559437
[TBL] [Abstract][Full Text] [Related]
25. Potential cost savings using GnRH agonists as preoperative therapy for uterine leiomyomas.
Saltiel E
Formulary; 1995 Sep; 30(9):532-4, 542. PubMed ID: 10161243
[TBL] [Abstract][Full Text] [Related]
26. Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor.
De Falco M; Staibano S; D'Armiento FP; Mascolo M; Salvatore G; Busiello A; Carbone IF; Pollio F; Di Lieto A
J Soc Gynecol Investig; 2006 May; 13(4):297-303. PubMed ID: 16697947
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of tibolone as "add-back therapy" in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids.
Morris EP; Rymer J; Robinson J; Fogelman I
Fertil Steril; 2008 Feb; 89(2):421-8. PubMed ID: 17572410
[TBL] [Abstract][Full Text] [Related]
28. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
[TBL] [Abstract][Full Text] [Related]
29. [Hormone therapy for uterine corpus cancer--introduction].
Sugiyama T; Izutsu T
Nihon Rinsho; 2004 Oct; 62 Suppl 10():370-4. PubMed ID: 15535270
[No Abstract] [Full Text] [Related]
30. [Morphometric and histological evaluation of uterine leiomyomas treated with GnRH agonists or progestational agents].
Resta L; Sanguedolce F; Orsini G; Laricchia L; Piscitelli D; Fiore MG
Pathologica; 2004 Apr; 96(2):35-41. PubMed ID: 15449444
[TBL] [Abstract][Full Text] [Related]
31. Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist.
Ichigo S; Takagi H; Matsunami K; Suzuki N; Imai A
Arch Gynecol Obstet; 2011 Sep; 284(3):667-70. PubMed ID: 21052701
[TBL] [Abstract][Full Text] [Related]
32. A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata.
Palomba S; Affinito P; Tommaselli GA; Nappi C
Fertil Steril; 1998 Jul; 70(1):111-8. PubMed ID: 9660431
[TBL] [Abstract][Full Text] [Related]
33. Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata.
Nakayama H; Yano T; Sagara Y; Kikuchi A; Ando K; Wang Y; Watanabe M; Matsumi H; Osuga Y; Momoeda M; Taketani Y
Gynecol Endocrinol; 1999 Dec; 13(6):382-9. PubMed ID: 10685331
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of raloxifene on bone mineral density and serum lipid levels in post-menopausal women with low BMD after discontinuation of hormone replacement therapy.
Song EK; Yeom JH; Shin HT; Kim SH; Shin WG; Oh JM
J Clin Pharm Ther; 2006 Oct; 31(5):421-7. PubMed ID: 16958819
[TBL] [Abstract][Full Text] [Related]
35. A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata.
Schlaff WD; Zerhouni EA; Huth JA; Chen J; Damewood MD; Rock JA
Obstet Gynecol; 1989 Dec; 74(6):856-62. PubMed ID: 2511532
[TBL] [Abstract][Full Text] [Related]
36. Lipid, glucose and homocysteine metabolism in women treated with a GnRH agonist with or without raloxifene.
Palomba S; Russo T; Orio F; Sammartino A; Sbano FM; Nappi C; Colao A; Mastrantonio P; Lombardi G; Zullo F
Hum Reprod; 2004 Feb; 19(2):415-21. PubMed ID: 14747190
[TBL] [Abstract][Full Text] [Related]
37. Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1.
Neven P; Quail D; Marin F; Creatsas G; Depypere H; Rechberger T; Liu-Léage S; Pavo I; Schmitt H; Nickelsen T
Maturitas; 2005 Oct; 52(2):87-101. PubMed ID: 15967604
[TBL] [Abstract][Full Text] [Related]
38. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma.
Walker CL; Burroughs KD; Davis B; Sowell K; Everitt JI; Fuchs-Young R
J Soc Gynecol Investig; 2000; 7(4):249-56. PubMed ID: 10964025
[TBL] [Abstract][Full Text] [Related]
39. Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production.
Britten JL; Malik M; Levy G; Mendoza M; Catherino WH
Fertil Steril; 2012 Nov; 98(5):1299-307. PubMed ID: 22901846
[TBL] [Abstract][Full Text] [Related]
40. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group.
Friedman AJ; Hoffman DI; Comite F; Browneller RW; Miller JD
Obstet Gynecol; 1991 May; 77(5):720-5. PubMed ID: 1901638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
